Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients...

Related Keywords

San Antonio ,Texas ,United States ,Italy ,Menarini Stemline ,Elcin Barker Ergun ,Cheya Pope ,Menarini Industrie Farmaceutiche Riunite ,Alex Zhavoronkov ,Valeria Speroni Cardi ,Menarini Group ,Stemline Therapeutics Inc ,San Antonio Breast Cancer Symposium ,Stemline Therapeutics ,Insilico Medicine ,Pharma Generative ,Industrie Farmaceutiche ,Brita Belli ,